Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Akebia Therapeutics (NQ: AKBA )

3.290 USD UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 12, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,454
Open 3.290
Bid (Size) 3.280 (25)
Ask (Size) 3.300 (1)
Prev. Close 3.290
Today's Range 3.290 - 3.290
52wk Range 2.090 - 13.71
Shares Outstanding 160,115,163
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Akebia Reports First Quarter 2021 Financial Results and Highlights Recent Company Milestones
- Vadadustat New Drug Application (NDA) submitted to the U.S. Food and Drug Administration (FDA) 
From PR Newswire
These Reddit Penny Stocks Are Soaring Today, Are They Worth Buying?
Tags Market News
From Penny Stocks to Buy, Picks, News and Information | PennyStocks.com - Feed

Performance

YTD
+12.67%
+12.67%
1 Month
+10.40%
+10.40%
3 Month
-28.79%
-28.79%
6 Month
+28.02%
+28.02%
1 Year
-71.54%
-71.54%

More News

Read More
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From PR Newswire
New England Journal of Medicine Publishes Results of Global Phase 3 Clinical Program of Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease
From PR Newswire
Akebia Therapeutics to Report First Quarter 2021 Financial Results and Discuss Recent Business Highlights
From PR Newswire
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Akebia Therapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
From PR Newswire
Akebia Therapeutics to Present at 20th Annual Needham Virtual Healthcare Conference
From PR Newswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From PR Newswire
Akebia Submits New Drug Application (NDA) to the FDA for Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis and Not on Dialysis
From PR Newswire
Akebia Therapeutics Announces Poster Presentations and Educational Symposium at National Kidney Foundation 2021 Virtual Spring Clinical Meetings
From PR Newswire
Akebia Therapeutics Announces Approval for Additional Indication of Riona® (ferric citrate hydrate) for the Treatment of Iron Deficiency Anemia in Adult Patients in Japan
From PR Newswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.